Fragment-Based Drug Discovery of KIF11 Inhibitors for Glioblastoma Treatment: Molecular Insights and Therapeutic Potential

Graphical Abstract

Fragment based novel drug identification and its validation through use of molecular dynamics and simulations.

Abstract

Comparing primary microcephaly genes with glioblastoma expression profiles reveals potential oncogenes, with proteins that support growth and survival in neural stem/progenitor cells likely retaining critical roles in glioblastoma. Identifying such proteins in familial and congenital microcephalic disorders offers promising targets for brain tumor therapy. Among these, KIF11, a kinesin motor protein (KSP), stands out as a significant oncogene. Expression analyses across various cancer types, including glioblastoma, demonstrate its overexpression in brain tumor patients. Using a targeted fragment-based drug discovery approach, we explored alternative small molecule inhibitors for KIF11. Existing drugs, such as ispinesib, are limited by side effects and multidrug resistance. Through molecular docking and simulations, we identified three candidate drug fragments. Further analysis confirmed that Mol-121026 exhibits a more stable interaction with KIF11 compared to ispinesib. Detailed analyses indicate that Mol-121026 binds to the same active site as the reference drug, effectively inhibiting KIF11ʼs mechano-chemical activity. Importantly, Mol-121026, a derivative of 3-phenyl-1H-pyrazol-5-carboxylic acid, offers a promising alternative due to its lower molecular complexity, ability to target allosteric sites, and potential for optimization into a potent and effective drug candidate. Our findings identified Mol-121026 as a top candidate with a docking score of −10.2 kcal/mol and MM/GBSA binding energy of −19.10 kcal/mol. Molecular dynamics simulations revealed stable interactions with key residues GLU116 and GLU118, supporting its potential as a promising KIF11 inhibitor.

Keywords

drug research - drug regulation - anticancer drugs - cancer - central nervous system disorders

^# QAN and CX should be considered joint first authors: Qais Ahmad Naseer, Cao Xuexian

Publication History

Received: 08 November 2024

Accepted: 05 January 2025

Article published online:
22 January 2025

• References

• 1 Hanif F, Muzaffar K, Perveen K. et al Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific journal of cancer prevention: APJCP 2017; 18: 3
• 2 Lang PY, Gershon TR. A new way to treat brain tumors: targeting proteins coded by microcephaly genes? Brain tumors and microcephaly arise from opposing derangements regulating progenitor growth. Drivers of microcephaly could be attractive brain tumor targets. Bioessays 2018; 40: 1700243
• 3 Iegiani G, Di Cunto F, Pallavicini G. Inhibiting microcephaly genes as alternative to microtubule targeting agents to treat brain tumors. Cell Death & Disease 2021; 12: 956
• 4 Erlanson DA, McDowell RS, OʼBrien T. Fragment-based drug discovery. Journal of medicinal chemistry 2004; 47: 3463-3482
• 5 Valensin S, Ghiron C, Lamanna C. et al KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?. BMC cancer 2009; 9: 1-14
• 6 Castillo A, Justice MJ. The kinesin related motor protein, Eg5, is essential for maintenance of pre-implantation embryogenesis. Biochemical and biophysical research communications 2007; 357: 694-699
• 7 Chauvière M, Kress C, Kress M. Disruption of the mitotic kinesin Eg5 gene (Knsl1) results in early embryonic lethality. Biochemical and biophysical research communications 2008; 372: 513-519
• 8 Kapoor TM, Mayer TU, Coughlin ML. et al Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. The Journal of cell biology 2000; 150: 975-988
• 9 Indorato R-L, DeBonis S, Garcia-Saez I. et al Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC. Frontiers in Oncology 2022; 12: 965455
• 10 Kinoshita M, Watanabe N. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 2007; 52: 1796-1799
• 11 Orth JD, Loewer A, Lahav G. et al Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Molecular biology of the cell 2012; 23: 567-576
• 12 Liu J, Tian Y, Yi L. et al High KIF11 expression is associated with poor outcome of NSCLC. Tumori Journal 2022; 108: 40-46
• 13 Guo Z, Huo X, Wu D. et al A Novel Variant of the KIF11 Gene, c. 2922G> T, Is Associated with Microcephaly by Affecting RNA Splicing. Developmental Neuroscience 2022; 44: 113-120
• 14 Blagden S, Molife L, Seebaran A. et al A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. British journal of cancer 2008; 98: 894-899
• 15 Sievert C. Interactive web-based data visualization with R, plotly, and shiny. 2020 Chapman and Hall/CRC. 470.
• 16 Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Chemical biology: methods and protocols 2015; 1263: 243-250
• 17 Eberhardt J, Santos-Martins D, Tillack AF. et al AutoDock Vina 1.2. 0: New docking methods, expanded force field, and python bindings. Journal of chemical information and modeling 2021; 61: 3891-3898
• 18 Purcell J, Reddy M, Davis J. et al Ispinesib (SB-715992) a kinesin spindle protein (KSP) inhibitor has single agent activity and enhances the efficacy of standard-of-care therapies in pre-clinical models of breast cancer. Cancer Research 2009; 69 (2_Supplement 2122
• 19 Sharma S, Sharma A, Gupta U. Molecular Docking studies on the Anti-fungal activity of Allium sativum (Garlic) against Mucormycosis (black fungus) by BIOVIA discovery studio visualizer 21.1. 0.0. Annals of Antivirals and Antiretrovirals 2021; 5: 028-032
• 20 Abraham MJ, Murtola T, Schulz R. et al GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015; 1: 19-25
• 21 Huang J, MacKerell AD. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. Journal of computational chemistry 2013; 34: 2135-2145
• 22 Vanommeslaeghe K, Hatcher E, Acharya C. et al CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of computational chemistry 2010; 31: 671-690
• 23 Mark P, Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. The Journal of Physical Chemistry A 2001; 105: 9954-9960
• 24 Bell J, Cao Y, Gunn J. et al PrimeX and the Schrödinger computational chemistry suite of programs. BioEssays 2012; 40: 534-538
• 25 Khoutoul M, Djedouani A, Lamsayah M. et al Liquid-liquid extraction of metal ions, DFT and TD-DFT analysis for some pyrane derivatives with high selectivity for Fe (II) and Pb (II). Separation Science and Technology 2016; 51: 1112-1123
• 26 Gautam RK, Singh PK, Sakthivel K. et al Analysis of pathogenic diversity of the rice bacterial blight pathogen (Xanthomonas oryzae pv. oryzae) in the Andaman Islands and identification of effective resistance genes. Journal of Phytopathology 2015; 163: 423-432
• 27 Li Q. Application of fragment-based drug discovery to versatile targets. Frontiers in molecular biosciences 2020; 7: 180
• 28 Kirsch P, Hartman AM, Hirsch AK. et al Concepts and core principles of fragment-based drug design. Molecules 2019; 24: 4309
• 29 Bon M, Bilsland A, Bower J. et al Fragment-based drug discovery—the importance of high-quality molecule libraries. Molecular Oncology 2022; 16: 3761-3777
• 30 Warner SL, Bashyam S, Vankayalapati H. et al Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Molecular cancer therapeutics 2006; 5: 1764-1773
• 31 Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clinical Pharmacology & Therapeutics 2008; 83: 673-691
• 32 Nandurkar D, Danao K, Rokde V. et al. Pyrazole Scaffold: Strategies toward the Synthesis and Their Applications, in Strategies for the Synthesis of Heterocycles and Their Applications. 2022 IntechOpen.